Trial reportNature medicine2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Erratum issued Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02662309 (A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder), which is not on this map. Cited by 314 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
314citing papers in PubMed, 5 pooled it
64.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
Who cites it
314 citing papers in PubMed, 5 syntheses or guidelines pooled it, 560 citations in OpenAlex.
- Pooled it
- Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes.World journal of urology · 2023Pooled it
- Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.Cell reports. Medicine · 2026Trial
- Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).World journal of urology · 2026Trial
- Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes.Frontiers in immunology · 2026Trial
- Trial
- Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.Journal for immunotherapy of cancer · 2025Trial
- Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.Nature communications · 2025Trial
- Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.Signal transduction and targeted therapy · 2024Trial
- Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.Nature cancer · 2024Trial
- Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.Nature communications · 2024Trial
- Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.Nature medicine · 2023Trial
- Trial
254 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
25 authors at 17 institutions in 6 countries.
Thomas PowlesBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. t.powles@qmul.ac.uk.ORCID http://orcid.org/0000-0001-7760-4724
Mark KockxHistogeneX N.V., Wilrijk, Belgium.
Alejo Rodriguez-VidaDepartment of Medical Oncology, Hospital del Mar, Barcelona, Spain.
Ignacio DuranInstituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain.
Simon J CrabbSouthampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0003-3521-9064
Michiel S Van Der HeijdenDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Bernadett SzabadosBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Albert Font PousCatalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Gwenaelle GravisInstitut Paoli-Calmettes, Marseille, France.
Urbano Anido HerranzDepartment of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0003-0376-5642
Andrew ProtheroeDepartment of Medical Oncology, Churchill Hospital, Oxford, UK.ORCID http://orcid.org/0000-0001-9413-0575
Alain RavaudDepartment of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU Bordeaux, Bordeaux, France.
Denis MailletDepartment of Medical Oncology, Hospital Lyon Sud, Lyon, France.
Maria Jose MendezDepartment of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain.ORCID http://orcid.org/0000-0002-7460-1859
Cristina SuarezVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
Mark LinchDepartment of Medical Oncology, University College London Hospital, London, UK.
Aaron PrendergastBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-9668-6689
Pieter-Jan van DamHistogeneX N.V., Wilrijk, Belgium.ORCID http://orcid.org/0000-0001-9074-8271
Diana StanoevaHistogeneX N.V., Wilrijk, Belgium.
Sofie DaelemansHistogeneX N.V., Wilrijk, Belgium.
Sanjeev MariathasanGenentech, San Francisco, CA, USA.
Joy S TeaGenentech, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3395-149X
Kelly MousaBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Romain Banchereau *Genentech, San Francisco, CA, USA.
Daniel Castellano *Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.
Queen Mary University of London · GBHistogen (United States) · USChurchill Hospital · GBComplejo Hospitalario Universitario de Santiago · ESHôpital Lyon Sud · FRHospital Del Mar · ESHospital Universitario Reina Sofía · ESInstitut Català d'Oncologia · ESInstituto de Biomedicina de Sevilla · ESInstitut Paoli-Calmettes · FRNIHR CRUK Experimental Cancer Medicine Centre · GBResearch Institute Hospital 12 de Octubre · ESThe Netherlands Cancer Institute · NLUniversitat Autònoma de Barcelona · ESUniversité de Bordeaux · FRUniversity College Hospital · GBUniversity of Antwerp · BE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers
Indexed as
AgedAntibodies, Monoclonal, HumanizedBiomarkers, TumorCarcinoma, Transitional CellDisease-Free SurvivalDNA RepairFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessTranscriptomeTransforming Growth Factor betaUrologic NeoplasmsAntibodies, Monoclonal, HumanizedatezolizumabBiomarkers, TumorTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02662309ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.